Table 1 Characteristics of the Two Study Groups Classified According to the Presence of a BALAD (Case Group) and no BALAD (Control Group) in Patients with CSC eyes
Variable | Cases (n, % or Mean ± SD) | Controls (n, % or Mean ± SD) | P Value |
|---|---|---|---|
Age (years) | 48.0 ± 11.9 | 48.2 ± 11.9 | 0.807* |
Gender | 0.945† | ||
Male | 28 (75.7) | 30 (75) | |
Female | 9 (24.3) | 10 (25) | |
Duration of symptoms | 1.000† | ||
aCSC | 7 (17.5) | 7 (17.5) | |
cCSC | 33 (82.5) | 33 (82.5) | |
Systemic disease | |||
Hypertension or CAD | 12 (30) | 8 (20) | 0.302† |
Psychiatric disorders | 13 (32.5) | 4 (10) | 0.014† |
Use of corticosteroids | 15 (37.5) | 4 (10) | 0.004† |
COVID-19 positivity | 4 (9.8) | None | 0.116‡ |
Previous treatment for CSC | 21 (52.5) | 12 (30) | 0.041† |
Photodynamic therapy | 12 (57.1) | 5 (50.0) | |
PDT and anti-VEGF | 1 (4.8%) | None | |
IVT anti-VEGF therapy | 3 (14.3) | 1 (10) | |
Mineralocorticoid antagonist | 2 (9.5) | 1 (10) | |
Mineralocorticoid antagonist and LA | None | None | |
LA | 2 (9.5) | 3 (30) | |
LA and anti-VEGF | 1 (4.8) | None | |
Treatment for CSC (follow-up) | 14 (35) | 11 (27.5) | |
Photodynamic therapy | 3 (21.4) | None | |
PDT and anti-VEGF | 1 (7.1) | None | |
IVT anti-VEGF therapy | 2 (14.3) | 3 (27.3) | |
Mineralocorticoid antagonist | 1 (7.1) | 2 (18.2) | |
Mineralocorticoid antagonist and LA | 1 (7.1) | None | |
LA | 4 (28.6) | 6 (54.5) | |
LA and anti-VEGF | 2 (14.3) | None | 0.469‡ |
Clinical characteristics | |||
Initial BCVA (logMAR) | 0.473 ± 0.39 | 0.390 ± 0.32 | 0.908** |
Final BCVA (logMAR) | 0.447 ± 0.30 | 0.341 ± 0.17 | 0.186** |
OCT | |||
Choroidal thickness (mean ± SD) | 448.7 ± 105.6 | 388.0 ± 82.0 | 0.036* |
Fibrin present | 13 (34.2) | 11 (44) | 0.434† |